- Open Access
Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching
© Lu et al; licensee BioMed Central Ltd. 2009
- Received: 11 September 2009
- Accepted: 25 September 2009
- Published: 25 September 2009
TDP-43 is an evolutionarily conserved RNA-binding protein implicated in the pathogenesis of frontotemporal dementia (FTD), sporadic and familial amyotrophic lateral sclerosis (ALS), and possibly other neurodegenerative diseases. In diseased neurons, TDP-43 is depleted in the nucleus, suggesting a loss-of-function pathogenic mechanism. However, the normal function of TDP-43 in postmitotic neurons is largely unknown.
Here we demonstrate that overexpression of Drosophila TDP-43 (dTDP-43) in vivo significantly increases dendritic branching of sensory neurons in Drosophila larvae. Loss of dTDP-43 function, either in a genetic null mutant or through RNAi knockdown, decreased dendritic branching. Further genetic analysis demonstrated a cell-autonomous role for dTDP-43 in dendrite formation. Moreover, human TDP-43 (hTDP-43) promoted dendritic branching in Drosophila neurons, and this function was attenuated by mutations associated with ALS.
These findings reveal an essential role for TDP-43 in dendritic structural integrity, supporting the notion that loss of normal TDP-43 function in diseased neurons may compromise neuronal connectivity before neuronal cell loss in FTD and ALS.
- Amyotrophic Lateral Sclerosis
- Sensory Neuron
- Frontotemporal Dementia
- Familial Amyotrophic Lateral Sclerosis
- Postmitotic Neuron
Frontotemporal lobar degeneration (FTLD) is a devastating age-dependent neurodegenerative condition primarily associated with impairments in cognition and social behaviors, as well as personality changes and other clinical abnormalities . Frontotemporal dementia (FTD), a major clinical syndrome of FTLD, is now recognized as the most common form of early-onset age-dependent dementia before the age of 60 . Increasing clinical, pathological, and molecular evidence indicates that FTD and amyotrophic lateral sclerosis (ALS) are closely related conditions .
In addition to pathogenic mutations in the microtubule binding protein tau [4, 5], rare mutations in other genes also cause FTD, such as those encoding valosin-containing protein, an AAA-type ATPase associated primarily with the endoplasmic reticulum , and CHMP2B, a component of the endosomal sorting complex required for transport III . Mutations in progranulin located on chromosome 17 also cause FTD in some patients without tau pathology [8, 9]. Progranulin is a secreted molecule, and many pathogenic mutations lead to progranulin haploinsufficiency. The pathogenic mechanism of FTD caused by progranulin deficiency is not known, but one of the pathological hallmarks is tau-negative and ubiquitin-positive neuronal inclusions that contain TDP-43 and its fragments [10–13]. Genetic mutations in TDP-43 are responsible for some sporadic and familial amyotrophic lateral sclerosis (ALS) [14–16], further reinforcing the notion that FTD and ALS are closely related conditions, referred to as TDP-43 proteinopathies . In healthy cells, TDP-43 mostly resides in the nucleus. In diseased neurons, however, TDP-43 is excluded from the nucleus and aggregates in the cytosol . Moreover, in axotomized motor neurons, TDP-43 expression is dramatically increased and becomes prominently localized in the cytosol . These findings raise the possibility that loss of the normal function of TDP-43, especially in the nucleus, contributes to the initiation or progression of disease.
TDP-43 is a ubiquitously expressed RNA-binding protein that contains two RNA recognition motifs, a glycine-rich region, a nuclear localization signal, and a nuclear export signal . It is not known which aspects of cellular physiology are regulated by TDP-43. TDP-43 is primarily localized in the nucleus at the active sites of transcription and cotranscriptional splicing in mammalian neurons . Indeed, limited experimental evidence indicates that TDP-43 is involved in transcription  and splicing [22, 23] and possibly in mRNA transport and local translation as well . TDP-43 and many other proteins form a large complex with Drosha , but its possible involvement in the microRNA pathway remains to be further explored. To understand how TDP-43 contributes to the pathogenesis of FTD and ALS, it is essential to dissect its normal functions in postmitotic neurons.
TDP-43 is highly conserved at the amino acid level from flies to humans, suggesting an evolutionarily conserved function [19, 23, 26]. To investigate the normal roles of TDP-43 in postmitotic neurons, we used dendrites of sensory neurons in the Drosophila peripheral nervous system (PNS) as our assay system and performed both gain- and loss-of-function genetic studies. We also examined the functional significance of some genetic mutations in TDP-43 that are associated with ALS. Our findings support the notion that a TDP-43 loss-of-function mechanism may contribute to the pathogenesis of FTD and ALS.
Fly strains and genetics
All flies were raised on standard food medium and kept at 25°C. dTDP-43 RNAi lines 38377 and 38379 were obtained from the Vienna Drosophila RNAi Center (VDRC). The dTDP-43Q 367Xmutant allele was identified from the Seattle Drosophila TILLING Project (Fly-TILL, Fred Hutchinson Cancer Research Center) using specific tilling primers (Additional file 1). dTDP-43Q 367X/CyO, GFP flies were crossed with Pin/CyO, GFP; Gal4221, UAS-mCD8-GFP to establish the stock dTDP-43Q 367X/CyO, GFP; Gal4221, UAS-mCD8-GFP/+. The Gal4221 driver was used to label ddaE and ddaF neurons with mCD8-GFP and drive the expression of transgenes . To visualize dendritic phenotypes of ddaE and ddaF neurons in third instar larvae, we crossed dTDP-43Q 367X/CyO, GFP; Gal4221, UAS-mCD8-GFP/+ flies with dTDP-43Q 367X/CyO, GFP or w1118 flies to generate dTDP-43Q 367X/dTDP-43Q 367X; Gal4221, UAS-mCD8-GFP/+ or dTDP-43Q 367X/+; Gal4221, UAS-mCD8-GFP/+ third instar larvae. For RNAi expression, dTDP-43Q 367X/CyO, GFP; Gal4221, UAS-mCD8-GFP/+ flies were crossed with UAS-dTDP-43 RNAi lines (VDRC 38377 and 38379) to generate dTDP-43Q 367X/+; Gal4221, UAS-mCD8-GFP/38377, and dTDP-43Q 367X/38379; Gal4221, UAS-mCD8-GFP/+ third instar larvae for phenotypic analysis. For transgene overexpression, Gal4221, UAS-mCD8-GFP flies were crossed with UAS-dTDP-43,, UAS-hTDP-43, UAS-hTDP-43-M337V, or UAS-hTDP-43-Q331K transgenic lines. In the above experiments, Gal4221, UAS-mCD8-GFP/+ third larvae served as the control.
Generation of transgenic Drosophila lines
Full-length hTDP-43 cDNA was cloned from HEK293 cells (provided by Dr. J.-A. Lee). To generate UAS-hTDP-43, UAS-hTDP-43-M337V, UAS-hTDP-43-Q331K, and UAS-hTDP-43- C-terminal fragment (amino acids 209-414) constructs, the corresponding primers (Additional file 1) were used to amplify DNA fragments, which were then cloned into the pUAST vector. To generate UAS-dTDP-43 constructs, the full-length dTDP-43 coding sequence was amplified from the cDNA plasmid GH09868 (Drosophila Genomics Resource Center) and cloned into the pUAST vector. These constructs were confirmed by sequencing and microinjected into wild-type (w1118) embryos to generate transgenic lines.
Antibody production and western blot
Anti-dTDP-43 polyclonal antibody was generated by immunizing rabbits with a peptide fragment spanning amino acids 179-192 (Thermo Fisher Scientific). For protein expression analysis, adult flies were frozen in ethanol with dry ice and vortexed to remove heads. Approximately 30 heads from each genotype were homogenized in 50 μl of lysis buffer (0.137 M NaCl, 20 mM Tris, pH 8.0, 10% glycerol, 1% NP-40, 0.1% SDS, 0.1% sodium deoxycholate, 1 mM DTT, Pierce protease inhibitors and phosphatase inhibitors). Homogenate was heated at 65°C for 10 min and centrifuged at 4°C for 10 min at 13,000 rpm. Protein concentrations were determined using Bradford Assay (Bio-Rad).
Supernatant containing 10 μg of protein was separated on a 10% acrylamide SDS gel and transferred to a PVDF membrane (Bio-Rad) in a wet transfer system at 4°C for 60 min at 100 V. The membrane was incubated in blocking solution containing 5% milk in TBST (25 mM Tris-HCl, 137 mM NaCl, 3 mM KCl, pH 7.4, and 0.1% Tween-20) at 4°C overnight, with dTDP-43 antibody (1:1000 in blocking solution) at room temperature for 3 h, and finally with anti-rabbit HRP-conjugated secondary antibody (Jackson Immunoresearch; 1:10,000) for 1 h. The signal was visualized with chemiluminescent substrate (Supersignal West Pico, Pierce). For other western blot analyses, the primary antibodies were hTDP-43 antibody (1:1000; 10782-2-AP, Proteintech), and β-actin antibody (1:1500; Cell Signaling).
Quantitative RT-PCR (qRT-PCR) analysis
Total RNAs were extracted from adult heads with Trizol (Invitrogen) and used as templates to generate cDNAs with TaqMan reverse transcription reagent (Applied Biosystems). cDNAs were used as templates for qRT-PCR in a final volume of 25 μl. A standard curve was run in each PCR reaction. Individual values were normalized to the value of the gene encoding the ribosomal protein RP-49. Two pairs of primers were designed to detect dTDP-43 transcripts (Additional file 2). All reactions were performed three times. Relative mRNA expression was calculated using the standard curve method and the delta-delta Ct method.
Mosaic analysis with a repressible cell marker (MARCM)
MARCM analysis of sensory neurons in the Drosophila PNS was performed as described . First, the dTDP-43Q 367Xallele was recombined onto the chromosome containing FRTG 13. FRTG 13, dTDP-43Q 367X/CyO or FRTG 13/CyO male flies were crossed with Gal4C 155, UAS-mCD8-GFP, hs-FLP1; FRTG 13, Gal80/CyO virgin females to generate Gal4C 155, UAS-mCD8-GFP, hs-FLP1/+; FRTG 13, Gal80/FRTG 13, dTDP-43Q 367Xand Gal4C 155, UAS-mCD8-GFP, hs-FLP1/+; FRTG 13, Gal80/FRTG 13embryos, respectively. Embryos from these crosses were collected on grape agar plates for 3 h in a 25°C incubator. The embryos were aged for 3 h and heat-shocked in a 37°C water bath for 40 min to induce mitotic recombination. The embryos were then kept in a moisture chamber at 25°C for 3-4 days. Third instar larvae were collected, and larvae that contained a single mCD8::GFP-labeled dorsal cluster PNS neuron were selected under a Nikon fluorescence dissection microscope. Images of the dendritic morphology of single DA neurons were recorded with a confocal microscope (Nikon, D-Eclipse C1). The significance of differences in dendritic branching complexity was determined with Student's t test.
Quantitative Analysis of dendritic ends of sensory neurons
The dendritic morphology of GFP-labeled dorsal sensory neurons was recorded with a confocal microscope (Nikon, D-Eclipse C1), and dendritic branches of ddaE or ddaF neurons in the A3 dorsal cluster were counted as described . Briefly, dendritic ends of DA neuron images were identified visually and highlighted with dots, which were counted with Adobe Photoshop software. The data were analyzed by Student's t test.
dTDP-43 promotes dendritic branching of sensory neurons in Drosophila
To examine neuronal functions of dTDP-43, we generated multiple UAS-dTDP-43 transgenic fly lines with insertion sites on different chromosomes. Because dendritic branching patterns are critically important for neuronal function and connectivity and dendritic defects are associated with many neurological disorders [29, 30], we focused our functional analysis of TDP-43 on dendrites. To do so, we used the sensory neurons in Drosophila larvae as our assay system, which has been useful in uncovering molecular mechanisms of dendritic morphogenesis . To drive transgene expression, we used the neuronal subtype-specific driver Gal4221, which targets gene expression in two sensory neurons only in each hemisegment .
dTDP-43 is required for normal viability of adult flies
Homozygosity for dTDP-43Q 367Xwas semi-lethal, with some mutant adult flies surviving to adulthood. For instance, the ratio of dTDP-43Q 367X/CyO to dTDP-43Q 367X/dTDP-43Q 367Xprogenies of dTDP-43Q 367X/CyO flies was about 4-5:1, instead of the expected 2:1 ratio for nonlethal mutations. This finding is consistent with a recent report that dTDP-43 deletion mutations in were semi-lethal as well . Expression of UAS-dTDP-43 RNAi (38377 or 38379, VDRC) driven by tubulin-Gal4 resulted in a similar lethal phenotype. Overexpression of dTDP-43 with the pan-neuronal Gal4C 155driver also led to a similar lethal phenotype, indicating that the proper level of dTDP-43 expression in the nervous system is required for normal viability. Indeed, ectopic expression of dTDP-43 in the eye caused a severe retinal degeneration phenotype (data not shown).
Loss of dTDP-43 activity reduces dendritic branching
Since ectopic overexpression of dTDP-43 markedly increased dendritic branching, it would be difficult to interpret results obtained by using the UAS-Gal4 system to rescue the dendritic phenotype in dTDP-43Q 367Xmutants. Therefore, to further confirm that loss of dTDP-43 activity reduces dendritic branching, we used two independent dTDP-43 RNAi lines obtained from VDRC to knock down dTDP-43 expression in these neurons. Again, the number of dendritic ends was decreased in ddaE (Figure 3C) and ddaF neurons (Figure 3D). These findings demonstrate that dTDP-43 has an essential role in patterning dendritic formation in vivo.
dTDP-43 has a cell-autonomous function in dendritic branching
hTDP-43 promotes dendritic branching in fly neurons and ALS-associated disease mutations attenuates this activity
Both of those ALS-associated mutant proteins promoted dendritic branching to a much lesser extent than wildtype hTDP-43 (Figure 6C). ddaE neurons expressing hTDP-43WT had 55 ± 1.6 (n = 29) dendritic ends but the neurons expressing hTDP-43M337V or hTDP-43Q331K had only 41.1 ± 1.5 (n = 18) or 44.3 ± 2.0 (n = 21) dendritic ends, respectively (P < 0.001) (Figure 6E). A similar effect was observed for ddaF neurons (Figure 6F). Thus, ALS-associated mutations in hTDP-43 attenuated its dendrite-promoting activity, raising the possibility that loss-of-function mechanism as a contributing factor to the disorder.
The pathological role of TDP-43 was first recognized by its presence in ubiquitin-positive but tau-negative inclusions in diseased neurons of FTD and ALS patients [10, 11]. TDP-43 pathology has two characteristic features. First, TDP-43 is proteolytically processed, and phosphorylated C-terminal fragments of approximately 20-25 kDa are present in the insoluble inclusions . Indeed, ectopic expression of these fragments in cultured cells results in aggregation . Second, TDP-43 is transported from the nucleus, where it predominantly resides in healthy cells. These findings suggest that TDP-43 may contribute to neurodegeneration through both a toxic gain-of-function mechanism and a loss-of-function mechanism. These possibilities are not mutually exclusive. However, the precise roles of TDP-43 in postmitotic neurons remain largely unknown.
Since TDP-43 is highly conserved at the amino acid sequence level from flies to humans, Drosophila offers a powerful model system to examine the endogenous functions of TDP-43. We obtained dTDP-43 null mutant flies and found that dTDP-43 is required for normal viability, consistent with a study published during the preparation of our manuscript . TDP-43 knockout mice have not been reported yet. Considering the high degree of conservation between dTDP-43 and hTDP-43, it is possible that TDP-43 is also essential for normal development in mammals. At the cellular level, multiple lines of evidence from our current study indicate that TDP-43 promotes dendritic branching in postmitotic neurons. This conclusion was based on overexpression studies, RNAi knockdown, and genetic analysis of a dTDP-43 null allele. TDP-43 seems to also regulate axonal structures at the Drosophila neuromuscular junction (NMJ) . These findings indicate an essential role for TDP-43 in neuronal structural integrity.
In many neurodegenerative diseases, defects in synaptic connections are probably one of the earliest alterations preceding neurodegeneration . Recent imaging studies in human brains suggest that specific functional connectivity networks are compromised in specific neurodegenerative conditions . It is conceivable that loss of the normal nuclear function of TDP-43 in specific vulnerable neurons reduces dendritic complexity, which in turn leads to compromised neuronal connectivity in that specific neuronal circuitry. Thus, exclusion of TDP-43 from the nucleus through unknown pathways in diseased neurons may represent a loss-of-function mechanism that may contribute to the pathogenesis of FTD and ALS.
Drosophila is also an excellent model system for studying human disease proteins. We found that hTDP-43 also promotes dendritic branching in Drosophila neurons, indicating a functional conservation. More importantly, two point mutations associated with ALS attenuated the dendrite-promoting activity of hTDP-43. Both are located in a C-terminal region that mediates protein-protein interactions . Thus, these mutations may compromise the normal functions of TDP-43 in neurons. It was reported that these missense mutations might also enhance the formation of TDP-43 aggregates . Thus, multiple pathogenic mechanisms may work in concert to promote disease initiation and/or progression.
Overexpression of dTDP-43 or hTDP-43 in vivo significantly increased dendritic branching in a Drosophila assay system. RNAi knockdown and genetic analysis of a dTDP-43 null allele revealed a cell-autonomous role for dTDP-43 in promoting dendrite formation. Mutations associated with some forms of ALS reduced the dendrite-promoting activity of hTDP-43, suggesting a loss-of-function pathogenic mechanism. These findings support the notion that loss of normal TDP-43 function may contribute to the pathogenesis of FTD and ALS. The fly model reported here and newly generated relevant reagents will facilitate studies to further elucidate the underlying molecular mechanisms.
We thank the Vienna Drosophila RNAi Center (VDRC) for providing dTDP-43 RNAi lines (38377 and 38379), the Seattle Drosophila TILLING Project for recovering TDP-43 truncation mutant Q367*, and Jin-A Lee for providing the human TDP-43 cDNA construct. We also thank S. Ordway for editorial assistance, S. Mitchell for administrative assistance, and lab members for comments. This work was supported by the NIH (F.-B.G.).
- Boxer AL, Miller BL: Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord. 2005, 19: S3-6. 10.1097/01.wad.0000183086.99691.91.View ArticlePubMedGoogle Scholar
- Vossel KA, Miller BL: New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol. 2008, 21: 708-716. 10.1097/WCO.0b013e328318444d.PubMed CentralView ArticlePubMedGoogle Scholar
- Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR: Frontotemporal lobar degeneration with FUS pathology. Brain. 2009,Google Scholar
- Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee VM: Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998, 282: 1914-1917. 10.1126/science.282.5395.1914.View ArticlePubMedGoogle Scholar
- Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, et al: Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998, 393: 702-705. 10.1038/31508.View ArticlePubMedGoogle Scholar
- Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE: Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004, 36: 377-381. 10.1038/ng1332.View ArticlePubMedGoogle Scholar
- Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Thusgaard T, et al: Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet. 2005, 37: 806-808. 10.1038/ng1609.View ArticlePubMedGoogle Scholar
- Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006, 442: 916-919. 10.1038/nature05016.View ArticlePubMedGoogle Scholar
- Cruts M, Gijselinck I, Zee van der J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, et al: Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006, 442: 920-924. 10.1038/nature05017.View ArticlePubMedGoogle Scholar
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006, 314: 130-133. 10.1126/science.1134108.View ArticlePubMedGoogle Scholar
- Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006, 351: 602-611. 10.1016/j.bbrc.2006.10.093.View ArticlePubMedGoogle Scholar
- Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL, Schneider JA, Kretzschmar HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A, Xu Y, Forman MS, Trojanowski JQ, Lee VM, Mackenzie IR: TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007, 171: 227-240. 10.2353/ajpath.2007.070182.PubMed CentralView ArticlePubMedGoogle Scholar
- Van Swieten JC, Heutink P: Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol. 2008, 7: 965-974. 10.1016/S1474-4422(08)70194-7.View ArticlePubMedGoogle Scholar
- Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE: TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008, 319: 1668-1672. 10.1126/science.1154584.View ArticlePubMedGoogle Scholar
- Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde Vande C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W, Meininger V, Dupre N, Rouleau GA: TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008, 40: 572-574. 10.1038/ng.132.View ArticlePubMedGoogle Scholar
- Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Mitsumoto H, Petersen RC, Cashman NR, Hutton M, Shaw CE, Boylan KB, Boeve B, Graff-Radford NR, Wszolek ZK, Caselli RJ, Dickson DW, Mackenzie IR, Petrucelli L, Rademakers R: Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008, 4: e1000193-10.1371/journal.pgen.1000193.PubMed CentralView ArticlePubMedGoogle Scholar
- Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, Xie SX, Kwong LK, Elman L, McCluskey L, Clark CM, Malunda J, Miller BL, Zimmerman EA, Qian J, Van Deerlin V, Grossman M, Lee VM, Trojanowski JQ: Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol. 2009, 66: 180-189. 10.1001/archneurol.2008.558.PubMed CentralView ArticlePubMedGoogle Scholar
- Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ: Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res. 2009, 1249: 202-211. 10.1016/j.brainres.2008.10.021.View ArticlePubMedGoogle Scholar
- Wang IF, Wu LS, Shen CK: TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol Med. 2008, 312: 479-485. 10.1016/j.molmed.2008.09.001.View ArticleGoogle Scholar
- Casafont I, Bengoechea R, Tapia O, Berciano MT, Lafarga M: TDP-43 localizes in mRNA transcription and processing sites in mammalian neurons. J Struct Biol. 2009, 167: 235-241. 10.1016/j.jsb.2009.06.006.View ArticlePubMedGoogle Scholar
- Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB: Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995, 69: 3584-3596.PubMed CentralPubMedGoogle Scholar
- Buratti E, Dörk T, Zuccato E, Pagani F, Romano M, Baralle FE: Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001, 20: 1774-1784. 10.1093/emboj/20.7.1774.PubMed CentralView ArticlePubMedGoogle Scholar
- Ayala YM, Pantano S, D'Ambrogio A, Buratti E, Brindisi A, Marchetti C, Romano M, Baralle FE: Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol. 2005, 348: 575-588. 10.1016/j.jmb.2005.02.038.View ArticlePubMedGoogle Scholar
- Wang IF, Wu LS, Chang HY, Shen CK: TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem. 2008, 105: 797-806. 10.1111/j.1471-4159.2007.05190.x.View ArticlePubMedGoogle Scholar
- Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R: The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004, 432: 235-240. 10.1038/nature03120.View ArticlePubMedGoogle Scholar
- Feiguin F, Godena VK, Romano G, D'Ambrogio A, Klima R, Baralle FE: Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett. 2009, 583: 1586-1592. 10.1016/j.febslet.2009.04.019.View ArticlePubMedGoogle Scholar
- Parrish JZ, Kim MD, Jan LY, Jan YN: Genome-wide analyses identify transcription factors required for proper morphogenesis of Drosophila sensory neuron dendrites. Genes Dev. 2006, 20: 820-835. 10.1101/gad.1391006.PubMed CentralView ArticlePubMedGoogle Scholar
- Li W, Wang F, Menut L, Gao F-B: BTB/POZ-zinc finger protein Abrupt regulates dendritic branching in a neuronal subtype-specific and dosage-dependent manner. Neuron. 2004, 43: 823-834. 10.1016/j.neuron.2004.08.040.View ArticlePubMedGoogle Scholar
- Parrish JZ, Emoto K, Kim MD, Jan YN: Mechanisms that regulate establishment, maintenance, and remodeling of dendritic fields. Annu Rev Neurosci. 2007, 30: 399-423. 10.1146/annurev.neuro.29.051605.112907.View ArticlePubMedGoogle Scholar
- Zoghbi HY: Postnatal neurodevelopmental disorders: meeting at the synapse?. Science. 2003, 302: 826-830. 10.1126/science.1089071.View ArticlePubMedGoogle Scholar
- Gao FB: Molecular and cellular mechanisms of dendritic morphogenesis. Curr Opin Neurobiol. 2007, 17: 525-532. 10.1016/j.conb.2007.08.004.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee T, Luo L: Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis. Neuron. 1999, 22: 451-461. 10.1016/S0896-6273(00)80701-1.View ArticlePubMedGoogle Scholar
- Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, Neumann M, Trojanowski JQ, Lee VM: Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem. 2009, 284: 8516-8524. 10.1074/jbc.M809462200.PubMed CentralView ArticlePubMedGoogle Scholar
- Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007, 8: 101-12. 10.1038/nrm2101.View ArticlePubMedGoogle Scholar
- Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD: Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009, 62: 42-52. 10.1016/j.neuron.2009.03.024.PubMed CentralView ArticlePubMedGoogle Scholar
- D'Ambrogio A, Buratti E, Stuani C, Guarnaccia C, Romano M, Ayala YM, Baralle FE: Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nuc Acids Res. 2009, 37: 4116-6126. 10.1093/nar/gkp342.View ArticleGoogle Scholar
- Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter1 J, Gitler AD: TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Bio Chem. 2009, 284: 20329-20339. 10.1074/jbc.M109.010264.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.